<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Irritable Bowel Syndrome | Family Medicine Reference</title>
  <style>
    body {
      font-family: "Segoe UI", Tahoma, Geneva, Verdana, sans-serif;
      background-color: #f8f9fa;
      color: #212529;
      line-height: 1.6;
      margin: 40px;
    }
    h1, h2, h3 {
      color: #004085;
    }
    section {
      background: #ffffff;
      border-radius: 8px;
      box-shadow: 0 2px 5px rgba(0,0,0,0.1);
      padding: 25px;
      margin-bottom: 20px;
    }
    table {
      width: 100%;
      border-collapse: collapse;
      margin: 10px 0;
    }
    th, td {
      border: 1px solid #dee2e6;
      padding: 10px;
      text-align: left;
    }
    th {
      background-color: #e9ecef;
    }
    .source {
      font-size: 0.9em;
      color: #555;
    }
    a {
      color: #0069d9;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
  </style>
</head>
<body>

  <h1>Irritable Bowel Syndrome (IBS)</h1>

  <section>
    <h2>Definition</h2>
    <p>
      Irritable bowel syndrome (IBS) is a <strong>chronic functional gastrointestinal disorder</strong> 
      characterized by recurrent abdominal pain associated with alterations in bowel habits 
      (stool frequency, form, or appearance) without structural or biochemical abnormalities.
    </p>
  </section>

  <section>
    <h2>Epidemiology</h2>
    <ul>
      <li>Very common in North America and Europe.</li>
      <li>More prevalent in women than men.</li>
      <li>Onset typically in young adulthood.</li>
    </ul>
  </section>

  <section>
    <h2>Pathophysiology</h2>
    <ul>
      <li>Altered gastrointestinal motility and visceral hypersensitivity.</li>
      <li>Disturbances in the gut–brain axis.</li>
      <li>Changes in gastrointestinal permeability and microbiota.</li>
      <li>Possible triggers: infection, stress, diet, psychological factors.</li>
    </ul>
  </section>

  <section>
    <h2>Clinical Presentation</h2>
    <ul>
      <li>Recurrent abdominal pain at least 1 day per week in the last 3 months, associated with two or more of the following:
        <ul>
          <li>Related to defecation.</li>
          <li>Change in stool frequency.</li>
          <li>Change in stool form (appearance).</li>
        </ul>
      </li>
      <li>May be associated with bloating, mucus in stool, or sensation of incomplete evacuation.</li>
      <li>Symptoms often worsen with stress or certain foods.</li>
    </ul>
  </section>

  <section>
    <h2>Rome IV Diagnostic Criteria</h2>
    <p>Diagnosis requires all of the following:</p>
    <ul>
      <li>Recurrent abdominal pain, on average, ≥1 day per week in the last 3 months.</li>
      <li>Associated with ≥2 of:
        <ul>
          <li>Pain related to defecation.</li>
          <li>Change in stool frequency.</li>
          <li>Change in stool form.</li>
        </ul>
      </li>
      <li>Symptom onset ≥6 months before diagnosis.</li>
    </ul>
  </section>

  <section>
    <h2>Subtypes (Based on Predominant Stool Pattern)</h2>
    <table>
      <tr><th>Subtype</th><th>Stool Pattern</th></tr>
      <tr><td>IBS-C</td><td>Constipation-predominant</td></tr>
      <tr><td>IBS-D</td><td>Diarrhea-predominant</td></tr>
      <tr><td>IBS-M</td><td>Mixed type (both constipation and diarrhea)</td></tr>
      <tr><td>IBS-U</td><td>Unclassified</td></tr>
    </table>
  </section>

  <section>
    <h2>Diagnostic Workup</h2>
    <ul>
      <li>Clinical diagnosis after excluding organic causes.</li>
      <li>Basic evaluation:
        <ul>
          <li>Complete blood count (CBC).</li>
          <li>C-reactive protein (CRP) or fecal calprotectin to exclude IBD.</li>
          <li>TSH if hypothyroidism suspected.</li>
          <li>Celiac serology (anti-TTG IgA) if diarrhea-predominant.</li>
        </ul>
      </li>
      <li>Alarm features that warrant further investigation:
        <ul>
          <li>Unintentional weight loss.</li>
          <li>Rectal bleeding or anemia.</li>
          <li>Family history of colon cancer, IBD, or celiac disease.</li>
          <li>Onset after age 50.</li>
        </ul>
      </li>
    </ul>
  </section>

  <section>
    <h2>Treatment</h2>
    <h3>1. Nonpharmacologic Therapy</h3>
    <ul>
      <li>Reassurance and patient education.</li>
      <li>Identify and avoid dietary triggers (e.g., caffeine, fatty foods, lactose, FODMAPs).</li>
      <li>High-fiber diet (for IBS-C) or low-FODMAP diet (for global IBS symptoms).</li>
      <li>Psychological interventions: cognitive-behavioral therapy, stress reduction, relaxation training.</li>
    </ul>

    <h3>2. Pharmacologic Therapy</h3>
    <table>
      <tr><th>Symptom Target</th><th>Medication Options</th></tr>
      <tr><td>Constipation (IBS-C)</td><td>Laxatives (polyethylene glycol), lubiprostone, linaclotide.</td></tr>
      <tr><td>Diarrhea (IBS-D)</td><td>Loperamide, bile acid sequestrants (cholestyramine), rifaximin, eluxadoline.</td></tr>
      <tr><td>Abdominal pain / global symptoms</td><td>Antispasmodics (hyoscine, dicyclomine), low-dose tricyclic antidepressants, SSRIs (for pain modulation).</td></tr>
    </table>
    <p><strong>Note:</strong> Pharmacologic choices should be individualized based on predominant symptoms and patient tolerance.</p>
  </section>

  <section>
    <h2>Prognosis</h2>
    <ul>
      <li>Chronic, fluctuating course.</li>
      <li>No increased risk of colorectal cancer or mortality.</li>
      <li>Quality of life may be significantly impacted; multidisciplinary care is often beneficial.</li>
    </ul>
  </section>

  <p class="source">
    Source: <a href="https://www.amboss.com/us/knowledge/irritable-bowel-syndrome?utm_medium=chatgpt-plugin&utm_source=chatgpt" target="_blank">
    AMBOSS: Irritable Bowel Syndrome</a>
  </p>

</body>
</html>
